• OUTLOOK ARENA
  • VIEWS ON NEWS
  • FEBRUARY 26, 2002

Ranbaxy: Leveraging on marketing setup

Ranbaxy has started leveraging on its direct marketing presence in 25 countries across the globe. Yesterday, the company announced entering into an agreement with Penwest, U.S granting Ranbaxy, exclusive marketing rights to market Nifedipine XL, a cardiovascular drug.

Ranbaxy would be marketing this drug on behalf of Penwest, USA in key Asian markets such as China, Malaysia, Singapore, Thailand and Sri Lanka. Cumulatively, all these regions have a market close to US$ 50 m for this drug. Though the ultimate revenue occurring to the company at this point of time may be small, it opens new vistas, as it would provide more such opportunities to leverage its marketing set up. Further, it will improve product offerings of the company in its key focus markets besides the US. An improving product basket would improve the bargaining power of the company. UK, Germany, Brazil and China are the other core markets identified by the company.

The speed at which Ranbaxy is cracking export markets is encouraging. The US subsidiaries of the company achieved sales in excess of US$ 113 m. It may be recalled that the company recently got approval for Cefuroxime Axetil in the US markets with expected sales revenues of around US$ 60m. Further, with aggressive product launches, Ranbaxy’s US subsidiaries are likely to cross revenues of US$ 200m in the current financial year.

Considering that most of the identified markets are logging healthy growth rates, the company should continue to log 16-18% CAGR growth over 2005 in exports. The company seems to be ahead of its target in achieving global sales in excess of US$ 1 bn by 2005.

Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

Equitymaster Agora Research Private Limited (Research Analyst)
103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407